AHA video: Kastrati talks ISAR trials, potential bivalirudin uptick in EU

TriMed Staff | | Cardiovascular Business | Structural Heart Disease
AHA: ISAR React - 73.55 Mb
ISAR REACT 4 trial, evaluating bivalirudin (Angiomax, The Medicines Company) led to better safety outcomes. Adnan Kastrati, MD, principal investigator of ISAR REACT 4, spoke with Cardiovascular Business about the findings of his 2011 AHA late-breaking clinical trial. Source: The Medicines Company
ORLANDO, Fla.—Adnan Kastrati, MD, principal investigator of ISAR REACT 4, sat down with Cardiovascular Business to discuss the results of the late-breaking clinical trial presented at the 2011 American Heart Association (AHA) conference, as well as how the ISAR trials have impacted interventional cardiology practice.

The trial showed that abciximab (ReoPro, Eli Lilly) plus unfractionated heparin, as compared with bivalirudin (Angiomax, The Medicines Company), increased the risk of bleeding in non–STEMI patients undergoing PCI, which may lead to an uptick in its use across Europe, which has slower rates of utilization.

This video was conducted collaboratively with ClinicalTrialResults.org.

TriMed Staff

Related Content

CMS proposes Medicare coverage for transcatheter tricuspid valve replacement
Hydra TAVR valve gains key approval as global reach continues to grow
SAVR outperforms TAVR in patients with bicuspid aortic valves
Treating AFib patients with TAVR still linked to elevated risks
Heart surgeons detail world’s first robotic heart procedure of its kind
Years of progress have made TAVR more effective when treating concomitant mitral stenosis

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.